Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2020-05, Vol.34 (5), p.1329-1341
Hauptverfasser: Cucco, Francesco, Barrans, Sharon, Sha, Chulin, Clipson, Alexandra, Crouch, Simon, Dobson, Rachel, Chen, Zi, Thompson, Joe Sneath, Care, Matthew A., Cummin, Thomas, Caddy, Josh, Liu, Hongxiang, Robinson, Anne, Schuh, Anna, Fitzgibbon, Jude, Painter, Daniel, Smith, Alexandra, Roman, Eve, Tooze, Reuben, Burton, Catherine, Davies, Andrew J., Westhead, David R., Johnson, Peter W. M., Du, Ming-Qing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1341
container_issue 5
container_start_page 1329
container_title Leukemia
container_volume 34
creator Cucco, Francesco
Barrans, Sharon
Sha, Chulin
Clipson, Alexandra
Crouch, Simon
Dobson, Rachel
Chen, Zi
Thompson, Joe Sneath
Care, Matthew A.
Cummin, Thomas
Caddy, Josh
Liu, Hongxiang
Robinson, Anne
Schuh, Anna
Fitzgibbon, Jude
Painter, Daniel
Smith, Alexandra
Roman, Eve
Tooze, Reuben
Burton, Catherine
Davies, Andrew J.
Westhead, David R.
Johnson, Peter W. M.
Du, Ming-Qing
description Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC / BCL2 -DH ( n  = 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with MYC / BCL2 -DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with MYC / BCL2 -DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour.
doi_str_mv 10.1038/s41375-019-0691-6
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7192846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A622499011</galeid><sourcerecordid>A622499011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c596t-4d6500e8ee950deb9c6c92ab0f3e0adcb9cc289c9c8561afaec9975375ce37303</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEokvhB3BBlpC4pbUd27EvSGXLl7SICxw4WV5nkrhK4mI7C_33dbRL25UA-TDyzDNjz8xbFC8JPiO4kueRkarmJSaqxEKRUjwqVoTVouSck8fFCktZl0JRdlI8i_EK4yUonhYnFZGMEcZWxe9LF5ObbEIdTJCcRbY3UwcRBdiBGRDs_DAn5ycTblCfYZ-tmRrUQ4Lglyw_RzT6Aew8mIC6YBpAvkWXm3frDfrlUo--_Fif5wtFjZ-3A5S9S8-LJ60ZIrw42NPi-4f339afys3Xj5_XF5vSciVSyRrBMQYJoDhuYKussIqaLW4rwKax2WGpVFZZyQUxrQGrVM3zWCxUdYWr0-Ltvu71vB2hsTClYAZ9HdyYO9LeOH0cmVyvO7_TNVFUMpELvD4UCP7nDDHpKz-HKf9ZU1ZzTDmX-L9UpYRkmNX0nurMANpNrc9P2tFFqy8EpUwpTEimzv5C5dPA6KyfoHXZf5Tw5kFCn9eW-nhYWzwGyR60wccYoL2bA8F6kZTeS0pnSelFUnrp_9XDAd5l_NFQBugeiDmUpRPuW_931VvuEtX5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2396840472</pqid></control><display><type>article</type><title>Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Cucco, Francesco ; Barrans, Sharon ; Sha, Chulin ; Clipson, Alexandra ; Crouch, Simon ; Dobson, Rachel ; Chen, Zi ; Thompson, Joe Sneath ; Care, Matthew A. ; Cummin, Thomas ; Caddy, Josh ; Liu, Hongxiang ; Robinson, Anne ; Schuh, Anna ; Fitzgibbon, Jude ; Painter, Daniel ; Smith, Alexandra ; Roman, Eve ; Tooze, Reuben ; Burton, Catherine ; Davies, Andrew J. ; Westhead, David R. ; Johnson, Peter W. M. ; Du, Ming-Qing</creator><creatorcontrib>Cucco, Francesco ; Barrans, Sharon ; Sha, Chulin ; Clipson, Alexandra ; Crouch, Simon ; Dobson, Rachel ; Chen, Zi ; Thompson, Joe Sneath ; Care, Matthew A. ; Cummin, Thomas ; Caddy, Josh ; Liu, Hongxiang ; Robinson, Anne ; Schuh, Anna ; Fitzgibbon, Jude ; Painter, Daniel ; Smith, Alexandra ; Roman, Eve ; Tooze, Reuben ; Burton, Catherine ; Davies, Andrew J. ; Westhead, David R. ; Johnson, Peter W. M. ; Du, Ming-Qing</creatorcontrib><description>Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC / BCL2 -DH ( n  = 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with MYC / BCL2 -DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with MYC / BCL2 -DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/s41375-019-0691-6</identifier><identifier>PMID: 31844144</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>14/32 ; 45/23 ; 631/208/2489 ; 631/208/68 ; Amino acids ; B-cell lymphoma ; Biomarkers, Tumor - genetics ; Burkitt's lymphoma ; Cancer ; Cancer Research ; Clonal Evolution ; Critical Care Medicine ; Female ; Gene expression ; Gene Expression Profiling ; Gene Expression Regulation, Leukemic ; Gene Rearrangement ; Gene sequencing ; Genetic aspects ; Genetic transformation ; Hematology ; Humans ; Immunoglobulins ; Intensive ; Internal Medicine ; Lymphocytes B ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphomas ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Mutation ; Mutation hot spots ; Myc protein ; Oncology ; Phenotype ; Phosphorylation ; Prognosis ; Proteins ; Proto-Oncogene Proteins c-bcl-2 - genetics ; Proto-Oncogene Proteins c-myc - genetics ; Survival Rate ; Translocation ; Translocation, Genetic ; Vincristine</subject><ispartof>Leukemia, 2020-05, Vol.34 (5), p.1329-1341</ispartof><rights>The Author(s) 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2019. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c596t-4d6500e8ee950deb9c6c92ab0f3e0adcb9cc289c9c8561afaec9975375ce37303</citedby><cites>FETCH-LOGICAL-c596t-4d6500e8ee950deb9c6c92ab0f3e0adcb9cc289c9c8561afaec9975375ce37303</cites><orcidid>0000-0002-0519-3820</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41375-019-0691-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41375-019-0691-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31844144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cucco, Francesco</creatorcontrib><creatorcontrib>Barrans, Sharon</creatorcontrib><creatorcontrib>Sha, Chulin</creatorcontrib><creatorcontrib>Clipson, Alexandra</creatorcontrib><creatorcontrib>Crouch, Simon</creatorcontrib><creatorcontrib>Dobson, Rachel</creatorcontrib><creatorcontrib>Chen, Zi</creatorcontrib><creatorcontrib>Thompson, Joe Sneath</creatorcontrib><creatorcontrib>Care, Matthew A.</creatorcontrib><creatorcontrib>Cummin, Thomas</creatorcontrib><creatorcontrib>Caddy, Josh</creatorcontrib><creatorcontrib>Liu, Hongxiang</creatorcontrib><creatorcontrib>Robinson, Anne</creatorcontrib><creatorcontrib>Schuh, Anna</creatorcontrib><creatorcontrib>Fitzgibbon, Jude</creatorcontrib><creatorcontrib>Painter, Daniel</creatorcontrib><creatorcontrib>Smith, Alexandra</creatorcontrib><creatorcontrib>Roman, Eve</creatorcontrib><creatorcontrib>Tooze, Reuben</creatorcontrib><creatorcontrib>Burton, Catherine</creatorcontrib><creatorcontrib>Davies, Andrew J.</creatorcontrib><creatorcontrib>Westhead, David R.</creatorcontrib><creatorcontrib>Johnson, Peter W. M.</creatorcontrib><creatorcontrib>Du, Ming-Qing</creatorcontrib><title>Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC / BCL2 -DH ( n  = 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with MYC / BCL2 -DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with MYC / BCL2 -DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour.</description><subject>14/32</subject><subject>45/23</subject><subject>631/208/2489</subject><subject>631/208/68</subject><subject>Amino acids</subject><subject>B-cell lymphoma</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Burkitt's lymphoma</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Clonal Evolution</subject><subject>Critical Care Medicine</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Leukemic</subject><subject>Gene Rearrangement</subject><subject>Gene sequencing</subject><subject>Genetic aspects</subject><subject>Genetic transformation</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphomas</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Mutation hot spots</subject><subject>Myc protein</subject><subject>Oncology</subject><subject>Phenotype</subject><subject>Phosphorylation</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins c-bcl-2 - genetics</subject><subject>Proto-Oncogene Proteins c-myc - genetics</subject><subject>Survival Rate</subject><subject>Translocation</subject><subject>Translocation, Genetic</subject><subject>Vincristine</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kk1v1DAQhiMEokvhB3BBlpC4pbUd27EvSGXLl7SICxw4WV5nkrhK4mI7C_33dbRL25UA-TDyzDNjz8xbFC8JPiO4kueRkarmJSaqxEKRUjwqVoTVouSck8fFCktZl0JRdlI8i_EK4yUonhYnFZGMEcZWxe9LF5ObbEIdTJCcRbY3UwcRBdiBGRDs_DAn5ycTblCfYZ-tmRrUQ4Lglyw_RzT6Aew8mIC6YBpAvkWXm3frDfrlUo--_Fif5wtFjZ-3A5S9S8-LJ60ZIrw42NPi-4f339afys3Xj5_XF5vSciVSyRrBMQYJoDhuYKussIqaLW4rwKax2WGpVFZZyQUxrQGrVM3zWCxUdYWr0-Ltvu71vB2hsTClYAZ9HdyYO9LeOH0cmVyvO7_TNVFUMpELvD4UCP7nDDHpKz-HKf9ZU1ZzTDmX-L9UpYRkmNX0nurMANpNrc9P2tFFqy8EpUwpTEimzv5C5dPA6KyfoHXZf5Tw5kFCn9eW-nhYWzwGyR60wccYoL2bA8F6kZTeS0pnSelFUnrp_9XDAd5l_NFQBugeiDmUpRPuW_931VvuEtX5</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Cucco, Francesco</creator><creator>Barrans, Sharon</creator><creator>Sha, Chulin</creator><creator>Clipson, Alexandra</creator><creator>Crouch, Simon</creator><creator>Dobson, Rachel</creator><creator>Chen, Zi</creator><creator>Thompson, Joe Sneath</creator><creator>Care, Matthew A.</creator><creator>Cummin, Thomas</creator><creator>Caddy, Josh</creator><creator>Liu, Hongxiang</creator><creator>Robinson, Anne</creator><creator>Schuh, Anna</creator><creator>Fitzgibbon, Jude</creator><creator>Painter, Daniel</creator><creator>Smith, Alexandra</creator><creator>Roman, Eve</creator><creator>Tooze, Reuben</creator><creator>Burton, Catherine</creator><creator>Davies, Andrew J.</creator><creator>Westhead, David R.</creator><creator>Johnson, Peter W. M.</creator><creator>Du, Ming-Qing</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0519-3820</orcidid></search><sort><creationdate>20200501</creationdate><title>Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit</title><author>Cucco, Francesco ; Barrans, Sharon ; Sha, Chulin ; Clipson, Alexandra ; Crouch, Simon ; Dobson, Rachel ; Chen, Zi ; Thompson, Joe Sneath ; Care, Matthew A. ; Cummin, Thomas ; Caddy, Josh ; Liu, Hongxiang ; Robinson, Anne ; Schuh, Anna ; Fitzgibbon, Jude ; Painter, Daniel ; Smith, Alexandra ; Roman, Eve ; Tooze, Reuben ; Burton, Catherine ; Davies, Andrew J. ; Westhead, David R. ; Johnson, Peter W. M. ; Du, Ming-Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c596t-4d6500e8ee950deb9c6c92ab0f3e0adcb9cc289c9c8561afaec9975375ce37303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>14/32</topic><topic>45/23</topic><topic>631/208/2489</topic><topic>631/208/68</topic><topic>Amino acids</topic><topic>B-cell lymphoma</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Burkitt's lymphoma</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Clonal Evolution</topic><topic>Critical Care Medicine</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Leukemic</topic><topic>Gene Rearrangement</topic><topic>Gene sequencing</topic><topic>Genetic aspects</topic><topic>Genetic transformation</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphomas</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Mutation hot spots</topic><topic>Myc protein</topic><topic>Oncology</topic><topic>Phenotype</topic><topic>Phosphorylation</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins c-bcl-2 - genetics</topic><topic>Proto-Oncogene Proteins c-myc - genetics</topic><topic>Survival Rate</topic><topic>Translocation</topic><topic>Translocation, Genetic</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cucco, Francesco</creatorcontrib><creatorcontrib>Barrans, Sharon</creatorcontrib><creatorcontrib>Sha, Chulin</creatorcontrib><creatorcontrib>Clipson, Alexandra</creatorcontrib><creatorcontrib>Crouch, Simon</creatorcontrib><creatorcontrib>Dobson, Rachel</creatorcontrib><creatorcontrib>Chen, Zi</creatorcontrib><creatorcontrib>Thompson, Joe Sneath</creatorcontrib><creatorcontrib>Care, Matthew A.</creatorcontrib><creatorcontrib>Cummin, Thomas</creatorcontrib><creatorcontrib>Caddy, Josh</creatorcontrib><creatorcontrib>Liu, Hongxiang</creatorcontrib><creatorcontrib>Robinson, Anne</creatorcontrib><creatorcontrib>Schuh, Anna</creatorcontrib><creatorcontrib>Fitzgibbon, Jude</creatorcontrib><creatorcontrib>Painter, Daniel</creatorcontrib><creatorcontrib>Smith, Alexandra</creatorcontrib><creatorcontrib>Roman, Eve</creatorcontrib><creatorcontrib>Tooze, Reuben</creatorcontrib><creatorcontrib>Burton, Catherine</creatorcontrib><creatorcontrib>Davies, Andrew J.</creatorcontrib><creatorcontrib>Westhead, David R.</creatorcontrib><creatorcontrib>Johnson, Peter W. M.</creatorcontrib><creatorcontrib>Du, Ming-Qing</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cucco, Francesco</au><au>Barrans, Sharon</au><au>Sha, Chulin</au><au>Clipson, Alexandra</au><au>Crouch, Simon</au><au>Dobson, Rachel</au><au>Chen, Zi</au><au>Thompson, Joe Sneath</au><au>Care, Matthew A.</au><au>Cummin, Thomas</au><au>Caddy, Josh</au><au>Liu, Hongxiang</au><au>Robinson, Anne</au><au>Schuh, Anna</au><au>Fitzgibbon, Jude</au><au>Painter, Daniel</au><au>Smith, Alexandra</au><au>Roman, Eve</au><au>Tooze, Reuben</au><au>Burton, Catherine</au><au>Davies, Andrew J.</au><au>Westhead, David R.</au><au>Johnson, Peter W. M.</au><au>Du, Ming-Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>34</volume><issue>5</issue><spage>1329</spage><epage>1341</epage><pages>1329-1341</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><abstract>Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for MYC / BCL2 double-hit ( MYC / BCL2 -DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC / BCL2 -DH ( n  = 62) by targeted sequencing and gene expression profiling. We showed that DLBCL with MYC / BCL2 -DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation. We identified frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival. DLBCL with MYC / BCL2 -DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive clinical behaviour.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31844144</pmid><doi>10.1038/s41375-019-0691-6</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-0519-3820</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-6924
ispartof Leukemia, 2020-05, Vol.34 (5), p.1329-1341
issn 0887-6924
1476-5551
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7192846
source MEDLINE; SpringerLink Journals
subjects 14/32
45/23
631/208/2489
631/208/68
Amino acids
B-cell lymphoma
Biomarkers, Tumor - genetics
Burkitt's lymphoma
Cancer
Cancer Research
Clonal Evolution
Critical Care Medicine
Female
Gene expression
Gene Expression Profiling
Gene Expression Regulation, Leukemic
Gene Rearrangement
Gene sequencing
Genetic aspects
Genetic transformation
Hematology
Humans
Immunoglobulins
Intensive
Internal Medicine
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphomas
Male
Medicine
Medicine & Public Health
Middle Aged
Mutation
Mutation hot spots
Myc protein
Oncology
Phenotype
Phosphorylation
Prognosis
Proteins
Proto-Oncogene Proteins c-bcl-2 - genetics
Proto-Oncogene Proteins c-myc - genetics
Survival Rate
Translocation
Translocation, Genetic
Vincristine
title Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A22%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20genetic%20changes%20reveal%20evolutionary%20history%20and%20heterogeneous%20molecular%20grade%20of%20DLBCL%20with%20MYC/BCL2%20double-hit&rft.jtitle=Leukemia&rft.au=Cucco,%20Francesco&rft.date=2020-05-01&rft.volume=34&rft.issue=5&rft.spage=1329&rft.epage=1341&rft.pages=1329-1341&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/s41375-019-0691-6&rft_dat=%3Cgale_pubme%3EA622499011%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2396840472&rft_id=info:pmid/31844144&rft_galeid=A622499011&rfr_iscdi=true